[go: up one dir, main page]

YU8004A - Vakcina protiv bolesti zapadnog nila - Google Patents

Vakcina protiv bolesti zapadnog nila

Info

Publication number
YU8004A
YU8004A YU8004A YUP8004A YU8004A YU 8004 A YU8004 A YU 8004A YU 8004 A YU8004 A YU 8004A YU P8004 A YUP8004 A YU P8004A YU 8004 A YU8004 A YU 8004A
Authority
YU
Yugoslavia
Prior art keywords
west nile
vaccine
provides
disease
vaccine composition
Prior art date
Application number
YU8004A
Other languages
English (en)
Inventor
Hsien-Jue Chu
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of YU8004A publication Critical patent/YU8004A/sh
Publication of RS53184B publication Critical patent/RS53184B/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Prikazani pronalazak obezbeđuje sigurnu i efikasnu kompoziciju vakcine protiv virusne bolesti zapadnog Nila. Imunogeno aktivna komponenta virusa zapadnog Nila ili plazmida DNK, pomoćne supstance kao što je ulje koje se metabolizuje i farmakološki prihvatljivog nosača je formulisano u imunizirajući vakcinu. Pronalazak takođe obezbeđuje postupak za sprečavanje ili ublažavanje bolesti zapadnog Nila, kao što je encefalitis kod ekvida davanjem kompozicije vakcine koja je ovde izložena.[The present invention provides a safe and effective vaccine composition against West Nile virus disease. An immunogenically active component of West Nile virus or plasmid DNA, an adjuvant such as a metabolizable oil, and a pharmacologically acceptable carrier are formulated into an immunizing vaccine. The invention also provides a method for the prevention or amelioration of West Nile disease, such as encephalitis, in equidae by administering the vaccine composition herein set forth.
YU8004A 2001-07-27 2002-07-23 Kompozicija vakcine za primenu u sprečavanju ili ublažavanju encefalitisa zapadnog nila kod ekvida RS53184B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30833401P 2001-07-27 2001-07-27
PCT/US2002/023447 WO2003061555A2 (en) 2001-07-27 2002-07-23 West nile vaccine

Publications (2)

Publication Number Publication Date
YU8004A true YU8004A (sh) 2006-08-17
RS53184B RS53184B (sr) 2014-06-30

Family

ID=27613166

Country Status (24)

Country Link
US (8) US7153513B2 (sh)
EP (3) EP2283858A3 (sh)
JP (2) JP4718778B2 (sh)
KR (2) KR20090053967A (sh)
CN (2) CN1273189C (sh)
AU (1) AU2002365244B2 (sh)
BE (1) BE2014C006I2 (sh)
BR (1) BRPI0211492B1 (sh)
CA (1) CA2452545C (sh)
CY (1) CY2014010I2 (sh)
DK (1) DK1427444T3 (sh)
ES (1) ES2435095T3 (sh)
FR (1) FR14C0016I2 (sh)
HR (1) HRP20040195B1 (sh)
HU (2) HU228690B1 (sh)
LU (1) LU92348I2 (sh)
ME (1) ME00491B (sh)
MX (1) MXPA04000680A (sh)
NZ (3) NZ570270A (sh)
PL (2) PL220846B1 (sh)
PT (1) PT1427444E (sh)
RS (1) RS53184B (sh)
WO (1) WO2003061555A2 (sh)
ZA (1) ZA200401596B (sh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425437B2 (en) * 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
PT1427444E (pt) * 2001-07-27 2013-11-19 Zoetis W Llc Vacina contra o vírus do nilo ocidental
EP1664786B1 (en) * 2003-09-09 2014-11-12 Idexx Laboratories, Inc. Detection of west nile virus infection and vaccination
US7074555B2 (en) * 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
CA2582534A1 (en) 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
CA2601705A1 (en) * 2005-04-01 2006-10-12 Wyeth Use of wnv dna vaccine in combination with a conventional vaccine to overcome immunogen interference
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
ATE507242T1 (de) 2005-05-12 2011-05-15 Crucell Holland Bv Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon
EP1724338A1 (en) * 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
WO2006122964A1 (en) * 2005-05-19 2006-11-23 Crucell Holland B.V. Methods for the production of a whole-inactivated west nile virus vaccine
US8048429B2 (en) 2005-06-24 2011-11-01 Intervet International B.V. Inactivated chimeric flavivirus
BRPI0617735B1 (pt) * 2005-10-19 2022-05-17 University Of Florida Research Foundation Inc Composições compreendendo vírus isolados, polinucleotídeos, ou polipeptídeos, construções de expressão, vacinas, kits para proteger um canino da infecção do vírus influenza, uso do vírus na preparação de composição farmacêutica bem como método in vitro para detecção de um vírus influenza que é capaz de infectar um animal canídeo
WO2007047728A2 (en) * 2005-10-20 2007-04-26 Wyeth Compositions and methods for the treatment of canine influenza virus disease
WO2007094854A2 (en) * 2005-12-14 2007-08-23 The Board Of Regents Of The University Of Oklahoma Rna virus vaccines and methods
CN101460519B (zh) 2006-06-06 2013-06-19 克鲁塞尔荷兰公司 具有杀灭葡萄球菌活性的人结合分子及其应用
CN101883581A (zh) 2007-11-06 2010-11-10 惠氏有限责任公司 猪肺炎支原体无毒力佐剂化活疫苗
AU2009248810B2 (en) 2008-05-23 2013-12-05 The Regents Of The University Of Michigan Nanoemulsion vaccines
US9642908B2 (en) * 2008-07-30 2017-05-09 University Of Kentucky Research Foundation Equine disease model for herpesvirus neurologic disease and uses thereof
CN102348466B (zh) * 2008-08-29 2014-05-07 贝林格尔.英格海姆维特梅迪卡有限公司 西尼罗病毒疫苗
BR112012008185A2 (pt) * 2009-10-07 2016-08-16 Wyeth Llc composições que compreendem adjuvante, macrolídeo e antígeno proteináceo, e métodos para uso dessas composições
BR122019023542B1 (pt) 2011-03-14 2022-02-15 Boehringer Ingelheim Vetmedica, Inc Composição imunogênica compreendendo uma ou mais cepas de vírus da rinite equina b (erbv) inativado e seu método de preparação
CN103045544B (zh) * 2011-10-17 2015-01-14 华中农业大学 预防西尼罗河病毒的重组假型杆状病毒Bac-G-prM/E及疫苗与应用
JP6505084B2 (ja) * 2013-05-14 2019-04-24 ゾエティス・サービシーズ・エルエルシー 免疫刺激性オリゴヌクレオチドを含む新規のワクチン組成物
MX2016002903A (es) * 2013-09-05 2016-06-06 Zoetis Services Llc Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah.
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
PL70842Y1 (pl) * 2017-08-25 2019-06-28 Gondek Lukasz Kuznia Mocy Urządzenie do regeneracji filtrów cząstek stałych i katalizatorów samochodowych
MX2021010343A (es) 2019-02-27 2022-01-18 Univ Rochester Vacuna para la influenza multivalente con virus vivo atenuado para la prevencion y el control del virus de la influenza equina (eiv) en caballos.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US308334A (en) 1884-11-18 Ladder
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US5741696A (en) * 1992-08-07 1998-04-21 Syntro Corporation Recombinant equine herpesviruses
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
NZ285324A (en) * 1994-05-10 1998-08-26 American Home Prod Vaccine containing modified live bovine respiratory syncytial virus (brsv) with an adjuvant and pharmaceutically acceptable carrier
IL139844A0 (en) 1998-06-04 2002-02-10 Us Gov Health & Human Serv Nucleic acid vaccines for prevention of flavivirus infection
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
JP4472250B2 (ja) * 2000-10-04 2010-06-02 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 高発現可能遺伝子
WO2002068637A2 (en) 2000-10-20 2002-09-06 Ribozyme Pharmaceuticals, Inc. Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
US20050048073A1 (en) 2001-02-28 2005-03-03 De Groot Anne S. Methods of determining west nile virus epitopes and method of using the same
EP1372711A4 (en) * 2001-03-12 2005-06-01 Univ Yale COMPOSITIONS AND METHODS OF WEST NIL VIRUS POLYPEPTIDES
US20030104008A1 (en) * 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
FR2823222B1 (fr) * 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
PT1427444E (pt) * 2001-07-27 2013-11-19 Zoetis W Llc Vacina contra o vírus do nilo ocidental
US7785799B2 (en) 2002-08-16 2010-08-31 The Board Of Regents Of The University Of Texas System Compositions and methods related to flavivirus envelope protein domain III antigens

Also Published As

Publication number Publication date
EP2283858A2 (en) 2011-02-16
US7153513B2 (en) 2006-12-26
WO2003061555A3 (en) 2004-04-15
PL368535A1 (en) 2005-04-04
PL398575A1 (pl) 2012-06-18
US20030091595A1 (en) 2003-05-15
JP4718778B2 (ja) 2011-07-06
MXPA04000680A (es) 2004-04-05
BRPI0211492B1 (pt) 2016-06-21
CN1935258B (zh) 2013-04-03
FR14C0016I2 (fr) 2015-07-24
US20070231350A1 (en) 2007-10-04
HK1066470A1 (en) 2005-03-24
PL212212B1 (pl) 2012-08-31
FR14C0016I1 (sh) 2014-03-28
HUP0401606A3 (en) 2005-02-28
JP2005515236A (ja) 2005-05-26
CY2014010I2 (el) 2024-02-16
US20070166802A1 (en) 2007-07-19
US7648705B2 (en) 2010-01-19
NZ531265A (en) 2008-08-29
PL220846B1 (pl) 2016-01-29
US7445787B2 (en) 2008-11-04
ES2435095T3 (es) 2013-12-18
PT1427444E (pt) 2013-11-19
DK1427444T3 (da) 2013-11-04
KR20090053967A (ko) 2009-05-28
CA2452545C (en) 2015-06-09
NZ570270A (en) 2010-08-27
ZA200401596B (en) 2005-07-27
ME00491B (me) 2011-10-10
WO2003061555A2 (en) 2003-07-31
CN1935258A (zh) 2007-03-28
US20070231349A1 (en) 2007-10-04
US20070166325A1 (en) 2007-07-19
KR20040028952A (ko) 2004-04-03
US20070166326A1 (en) 2007-07-19
CY2014010I1 (el) 2020-05-29
HRP20040195B1 (hr) 2014-07-18
CA2452545A1 (en) 2003-07-31
EP1427444A4 (en) 2008-01-02
RS53184B (sr) 2014-06-30
HRP20040195A2 (en) 2004-08-31
AU2002365244B2 (en) 2007-12-06
LU92348I9 (sh) 2019-01-02
JP2011057692A (ja) 2011-03-24
HUP0401606A2 (hu) 2004-11-29
EP2281572A1 (en) 2011-02-09
HU228690B1 (en) 2013-05-28
US20070178119A1 (en) 2007-08-02
LU92348I2 (fr) 2014-09-22
EP2283858A3 (en) 2011-03-23
CN1273189C (zh) 2006-09-06
BR0211492A (pt) 2004-08-17
CN1535157A (zh) 2004-10-06
EP1427444A2 (en) 2004-06-16
EP1427444B1 (en) 2013-08-21
HUS1300055I1 (hu) 2016-08-29
NZ553165A (en) 2008-09-26
US20070166324A1 (en) 2007-07-19
BE2014C006I2 (sh) 2021-02-04
US7648706B2 (en) 2010-01-19

Similar Documents

Publication Publication Date Title
YU8004A (sh) Vakcina protiv bolesti zapadnog nila
GB0025577D0 (en) Vaccine
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
IL202978A0 (en) West nile virus vaccine
WO2002009643A3 (en) Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
IL154913A0 (en) Composition comprising immunogenic microparticles
SG156666A1 (en) Vaccines against japanese encephalitis virus and west nile virus
CY1112120T1 (el) Ενα εμβολιο σκυλου για προστασια απο την ερλιχιωση
WO2003059385A3 (en) Hiv vaccine and method of use
WO2003051288A3 (en) Mycobacterial vaccine
WO2001097841A3 (en) Qs-21 and il-12 as an adjuvant combination
MXPA02010173A (es) Antigenos de leishmania para utilizarse en la terapia y el diagnostico de leishmaniasis.
WO2002028362A3 (fr) Composition vaccinale et procede de stabilisation
MY153290A (en) Multivalent avian influenza vaccines
MXPA05009447A (es) Vacunas bovinas con adyuvante.
WO2001064244A3 (en) In ovo protection against infectious bronchitis
SG147465A1 (en) Vaccine
BR0112486A (pt) Poliproteìna, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição farmacêutica, e, método para imunizar um indivìduo contra hiv
WO2003030935A3 (en) Adjuvants for nucleic acid vaccines
PL348550A1 (en) Ibdv mutant, vaccine containing it for protecting poultry against a disease caused by ibdv and method of protecting poultry against such disease
BRPI0508660A (pt) composição de vacina eficaz na prevenção ou melhora da infecção por vìrus da doença bursal infecciosa; composição de vacina; isolado antigênico do vìrus da doença bursal infecciosa; e método para induzir proteção contra infecção do vìrus da doença bursal infecciosa
CY1114624T1 (el) Εμβολιο δυτικου νειλου
WO2004064784A3 (en) Composition and method for preventing or treating a virus infection
WO2002096940A3 (en) Attenuated very virulent infectious bursal disease virus
HK1068502A1 (en) Passive immunisation against bacillus anthracis